LEBANON, N.H.--(BUSINESS WIRE)--Adimab, Inc., a biotechnology company developing a human antibody discovery platform in yeast, today announced the closing of Series B financing. The total amount of the financing was not disclosed. The round was co-led by Polaris Venture Partners and SV Life Sciences, both of whom were previous investors in Adimab.
